399275 SZSE ChiNext Healthcare Index
- 2966.68
- -44.89-1.49%
Delayed hospital purchases, sluggish non-rigid medical demand, and other factors dragged down shenzhen mindray bio-medical electronics' Q3 net income by 9.31% | Financial report watch
Due to factors such as delayed hospital procurement, tight hospital construction funds, and sluggish non-rigid medical demand, in the third quarter, Shenzhen Mindray Bio-Medical Electronics' net income decreased by 9.31% year-on-year, while total revenue increased by 1.43% year-on-year. In the second interim profit distribution in 2024, Shenzhen Mindray Bio-Medical Electronics will distribute 16.50 yuan for every 10 shares.
Q3 revenue growth rate dropped to 1%. Can the next approved botox product in China be featured on imeik technology development? | Interpretations
①In the first three quarters, imeik technology development's performance has shown some growth, but the revenue and net income attributable to shareholders have slowed down. ②In order to seek new growth points, imeik technology development's research and development expenses continue to rise, focusing on the layout of weight management drugs, botulinum toxin and other fields.
imeik technology development Q3 revenue increased by 1.10% year-on-year, net income increased by 2.13% | Financial Report Watch
In the first three quarters, the company achieved revenue of approximately 2.376 billion yuan, a year-on-year increase of 9.46%; net income was approximately 1.586 billion yuan, a year-on-year increase of 11.79%. The operational scale of the company is steadily increasing, and the profitability meets market expectations.
Investors further inquired about the progress of the GLP-1 new drug review. Hebei Changshan Biochemical Pharmaceutical responded that the registration inspection has been completed and the approval time cannot be estimated. Directly focus on the earnings
①At today's earnings conference, investors repeatedly inquired about the progress and approval time of the GLP-1 drug Aibonapeptide injection, with management stating that it is unpredictable; ②Management revealed that the on-site verification and registration inspection of Aibonapeptide have been completed, and clinical trials for weight loss indications have not yet been initiated; ③Regarding the decline in performance compared to multiple quarters, management stated that they will speed up going global to restore the profitability of the heparin business.
Long-serving senior executive of lepu medical technology resigns, can the second generation successor stop the decline in performance? | Express announcement
①Tonight, lepu medical technology announced that General Manager Zhang Zhibin and Deputy General Manager Zheng Guorui resigned, and the Chairman's daughter Pu Fei took over as General Manager, with a "sea turtle elite" background; ②Starting from 2023, lepu medical technology's performance has declined for several consecutive quarters, and the market cap has dropped by one quarter compared to its peak period.
The threat of additional tariffs looms high, intco medical technology's stock price drops by 20%, What are the prospects for its North American layout?
①Today, Intco Medical Technology's stock fell 20 centimeters in the intraday trading session. An employee from the securities department of Intco Medical Technology stated, 'This is because the United States announced the impact of increasing tariffs on some Chinese commodities under Section 301.' ②The employee said that the proportion of the U.S. market in the company's revenue is about 35%, which may pose challenges to the company's performance in the short term. However, the overall potential of the U.S. market is still significant, and the company still plans to increase its efforts to expand into the North American market.
Contec Medical Systems: Will increase layout efforts in Africa, and multiple in-vitro diagnostic products are expected to be registered within the year.|Focus on the earnings conference
① The decline in performance in the first half of the year is attributed to a reduction in orders due to downstream customers destocking and a high base from the previous year; ② Currently, bulk production of zirconia ceramic blocks for all-ceramic dentures has been achieved, and multiple ex vivo diagnostic products have entered the late stage of development, with registration expected to be completed within the year; ③ The company has made market breakthroughs in several countries in Africa and will continue to focus on the African market, increasing product distribution and marketing efforts.
Tsubota Lab has signed an exclusive implementation license agreement with shenyang xingqi pharmaceutical.
On the 5th, Tobita Lab <4890> announced that they have signed a patent license agreement with China's ophthalmology drug manufacturer Shenyang Xingqi Pharmaceutical (hereinafter referred to as Xingqi) to grant exclusive rights to certain patents in specific regions.
Another unreasonable suppression! The U.S. House of Representatives has passed the Biosecurity Act, and wuxi apptec and wuxi bio have quickly responded.
①The U.S. House of Representatives passed the draft of the Biosecurity Act (H.R.8333) with 306 votes in favor and 81 votes against. ②Wuxi Apptec, Wuxi Bio, and other companies strongly opposed it. ③This bill still needs to be voted on by the Senate and the versions passed by both houses need to be reconciled before it can be submitted to the U.S. President for signing into law.
chongqing zhifei biological products' 23-valent pneumonia vaccine joins the "price reduction group" just one year after its launch.
① Chongqing Zhifei Biological Products 23-valent pneumococcal polysaccharide vaccine has lowered its online price by nearly 30% in provinces such as Jiangsu and Jilin; ② Currently, China's pneumococcal vaccine market is showing a competitive situation of "wrestling" between overseas MNCs and domestic companies, and more and more companies are expanding their presence in this field; ③ Industry experts believe that in order to occupy the market, companies can only choose to actively reduce prices.
The batch issuance of the quadrivalent HPV vaccine has dramatically decreased, and chongqing zhifei biological products' revenue and net profit have both declined. Interpretation of the financial report.
Due to the decrease in sales volume of H1's main products, Chongqing Zhifei Biological Products reported a decrease in revenue and net income in its semi-annual report. The volume of Merck's quadrivalent HPV vaccine, which the company represents, decreased by more than 90% compared to the previous year. With the accelerated development of domestically-produced nine-valent HPV vaccines, the company's pressure will further increase.
Core business revenue and gross margin both declined, with Apichope Pharmaceutical's net profit in the first half of the year significantly reduced. Interpreting financial reports.
Affected by changes in the external market environment and internal business adjustments, apichope pharmaceutical's revenue and net profit both declined in H1. Previously, the company was fined by the medical insurance bureau for false labelling, in addition to returning a large amount of funds, it was also suspended from participating in national procurement qualifications for 6 months.
Intense market competition combined with inventory reduction, Shenzhen Kangtai Biological Products' performance in the first half of the year has significantly declined | Interpretation of financial reports
①Affected by market competition and factors such as inventory reduction, the total revenue and net income attributable to the mother of shenzhen kangtai biological products declined in H1. ②The sales revenue of the business sector with the largest revenue contribution of the company decreased by more than 30% year-on-year. ③The accounts receivable of shenzhen kangtai biological products continued to climb, with a substantial decrease in cash flow.
Sanbo Brain H1 net profit increased by more than 50% year-on-year, industry attention on expansion phase performance sustainability | Interpretations
①In the first half of this year, Sanbo Neurology achieved double growth in operating profit, mainly due to the expansion of the business scale and the increase in net income from acquiring companies; ② Sanbo Neurology is building two hospitals and plans to focus on the future expansion in the cni yangtze index and cni zhujiang index regions; ③ The industry is concerned about the sustainability of its expansion, the construction capabilities of the diagnostic and treatment team, and the relatively scarce professional talents in neurology.
Zhejiang Jolly Pharmaceutical: The regions that won the centralized procurement bids have basically achieved volume-based pricing and will develop 10 varieties of Wuling series.
①The company has seen both gains and losses in centralized procurement, for example, sales in centralized procurement areas have increased significantly compared to non-centralized procurement areas, but the company once lost the bid in the procurement of Bacillus Subtilis; ②Due to the reduction of sales expenses and other reasons, the net income of the company in the areas where it won the bid in centralized procurement has actually increased; ③Currently, the company's production capacity utilization rate of Trametes versicolor powder is relatively high and expansion projects for the second phase are underway, with future considerations for planning new production capacity.
Hybio Pharmaceutical's H1 revenue continues to decline. Are active pharmaceutical ingredients becoming a 'lifesaver' for large orders? | Interpretations
①In the first half of this year, the revenue decline trend of Hybio Pharmaceutical has not been stopped, and the net profit loss has narrowed to some extent; ②The revenue of the formulation sector continues to decline due to the impact of block orders for main products, and the revenue contribution of the active pharmaceutical ingredient sector has become the first; ③In the first half of this year, Hybio Pharmaceutical has made some efforts to alleviate the cash flow.
The gross margin of injection products in the solution category has declined, and the imeik technology development's Q2 performance growth rate has dropped to single digits| Speed reading announcement.
①Imeik Technology Development's H1 revenue and net income growth rate slowed down. ②The gross margin of solution injection products has declined, and its proportion in total revenue has further decreased. ③In addition to laying out research and development pipelines for botulinum toxin, GLP-1 drugs, the company is also further expanding in the medical beauty equipment field.
Director of Shandong Jincheng Pharmaceutical Group investigated for suspected stock market manipulation. Q1 performance just turned around according to announcement.
On the evening of today, Shandong Jincheng Pharmaceutical Group announced that its actual controller and chairman, Zhao Yeqing, was under investigation for suspected illegal acts of market manipulation by the China Securities Regulatory Commission. Zhao Yeqing has been the chairman of Jincheng Pharmaceutical Group for 13 years. The last time he appeared in public was at the 3rd China Pharmaceutical and Chemical Conference two days ago. In Q1 of 2024, Jincheng Pharmaceutical Group has shown a good trend of reversing last year's poor performance.
AH trends diverge, Hang Seng Index up 0.6%, CNOOC up 4%, national bond futures slightly rebound.
Rare earth permanent magnets concept stocks pull back, photovoltaic and lithography themes also weaken. Hong Kong's real estate, banks, and oil & gas stocks are strong, CNOOC up 4%, Agricultural Bank of China and China Merchants Bank rise more than 2%. After experiencing a sharp drop yesterday, national bond futures rebounded in early trading, with 10-year and 30-year national bond futures contracts rising nearly 0.1% in early trading.
Hangzhou Tigermed Consulting Reports FY Results